Showing results (2601-2610 of 2,814) with videos related to

Sort By:
Pageof 282
Journal for Immunotherapy of Cancer|March 3, 2026
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term dataTessa F Flores, Emily S Tonorezos, Shailender Bhatia, et al.
Nature Medicine|May 9, 2024
Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitisMolly Fisher Thomas, Kamil Slowikowski, Kasidet Manakongtreecheep, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
British Journal of Cancer|October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysisPrachi Bhave, Lalit Pallan, Georgina V Long, et al.
The Spine Journal : Official Journal of the North American Spine Society|June 4, 2021
Cervical fusion for treatment of degenerative conditions: development of appropriate use criteriaCharles A Reitman, Jeffrey M Hills, Christopher J Standaert, et al.
The British Journal of Dermatology|March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational studyXue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.
Investigative Ophthalmology & Visual Science|June 30, 2004
Identification of KIF21A mutations as a rare cause of congenital fibrosis of the extraocular muscles type 3 (CFEOM3)Koki Yamada, Wai-Man Chan, Caroline Andrews, et al.
Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.
Cancer Discovery|December 17, 2017
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J Sullivan, Jeffrey R Infante, Filip Janku, et al.
Pageof 282